StageZero Life Sciences Ltd. (SZLSF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
StageZero Life Sciences Ltd. (SZLSF) trades at $0.001. StageZero Life Sciences Ltd. focuses on early disease detection and personalized health management through molecular diagnostic testing. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for SZLSF: SZLSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SZLSF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SZLSF: 3/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →StageZero Life Sciences Ltd. (SZLSF) Healthcare & Pipeline Overview
StageZero Life Sciences Ltd. is a vertically integrated healthcare company specializing in molecular diagnostic tests for early disease detection, primarily focusing on cancer. Their core technology, Sentinel Principle, powers the Aristotle multi-cancer screening test, positioning them in the personalized health management sector within the US and Canada.
What Is the Investment Thesis for SZLSF?
StageZero Life Sciences Ltd. presents a compelling, albeit high-risk, investment case centered on its Aristotle multi-cancer screening test. The company's Sentinel Principle platform offers a potential competitive edge in early cancer detection. Key value drivers include successful commercialization of Aristotle, expansion of its testing portfolio, and strategic partnerships with healthcare providers. The company's small market capitalization and OTC listing introduce significant volatility and liquidity risks. The path to profitability hinges on achieving substantial revenue growth and managing operational expenses effectively. Investors should closely monitor adoption rates of Aristotle and progress in securing reimbursement coverage from payers. The company's gross margin of 1.0% indicates a need for improved cost management.
Based on FMP financials and quantitative analysis
SZLSF Key Highlights
- Aristotle is a multi-cancer panel test designed to screen for multiple cancers simultaneously from a single blood sample, offering a convenient and potentially cost-effective screening solution.
- Sentinel Principle is StageZero's proprietary platform technology that identifies novel biomarkers from whole blood, enabling the development of highly sensitive and specific diagnostic tests.
- ColonSentry is a blood test offered by StageZero to determine an individual's current risk for having colorectal cancer.
- The company has a small market capitalization of $0.00B, indicating a high-risk, high-reward investment profile.
- StageZero operates in the growing market of early cancer detection and personalized health management.
Who Are SZLSF's Competitors?
SZLSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EXAS Exact Sciences Corporation | $104.91 | +0.00% | $20.0B | 62 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| SQIDF SQI Diagnostics Inc. | $0.01 | +14.62% | $6.07M | 64 |
| ANPCF Cellbxhealth PLC | $0.02 | +0.00% | $6.53M | 59 |
| JMPHF Leveljump Healthcare Corp. | $0.04 | +0.00% | $8.12M | 55 |
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| ADVB Advanced Biomed Inc. Common Stock | $8.90 | +76.94% | $9.63M | 51 |
| BNR Burning Rock Biotech Limited | $10.07 | +1.00% | $10.6M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SZLSF's Key Strengths?
- Proprietary Sentinel Principle platform
- Aristotle multi-cancer panel test
- Vertically integrated business model
- Focus on early disease detection
- Experienced management team
What Are SZLSF's Weaknesses?
- Limited financial resources
- Small market capitalization
- Dependence on Aristotle test
- Low gross margin
- OTC listing
What Could Drive SZLSF Stock Higher?
- Expansion of Aristotle test menu to include additional cancer types.
- Securing reimbursement coverage from government and private payers.
- Strategic partnerships with healthcare providers to integrate Aristotle into routine screening protocols.
What Are the Key Risks for SZLSF?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established diagnostic companies with greater financial resources.
- Regulatory hurdles and delays in obtaining approvals for new diagnostic tests.
- Reimbursement challenges and the risk of payers not covering the cost of Aristotle.
- Technological obsolescence and the emergence of new diagnostic technologies.
- Limited financial resources and the need to raise additional capital to fund operations.
What Are the Growth Opportunities for SZLSF?
- Expansion of Aristotle Test Menu: StageZero has the opportunity to expand the Aristotle test menu to include additional cancer types and biomarkers. This would increase the test's value proposition and addressable market, potentially driving revenue growth.
- Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and physician groups to integrate Aristotle into routine screening protocols represents a major growth opportunity. These partnerships could provide access to a large patient base and accelerate adoption of the test. Timeline for establishing these partnerships is ongoing.
- Geographic Expansion: While currently focused on the US and Canada, StageZero could expand its operations to other international markets. This would require regulatory approvals and market entry strategies, but could significantly increase the company's long-term growth potential. Expansion into Europe and Asia is a potential long-term goal.
- Securing Reimbursement Coverage: Obtaining favorable reimbursement coverage from government and private payers is crucial for driving widespread adoption of Aristotle. Successful negotiations with payers would significantly reduce the out-of-pocket cost for patients and increase the test's accessibility. This is an ongoing process.
- Development of New Diagnostic Tests: Leveraging its Sentinel Principle platform, StageZero can develop new diagnostic tests for other diseases beyond cancer. This would diversify the company's product portfolio and reduce its reliance on Aristotle. Focus could be on other chronic diseases with large unmet needs.
What Opportunities Does SZLSF Have?
- Expansion of Aristotle test menu
- Strategic partnerships with healthcare providers
- Geographic expansion
- Securing reimbursement coverage
- Development of new diagnostic tests
What Threats Does SZLSF Face?
- Competition from established diagnostic companies
- Regulatory hurdles
- Reimbursement challenges
- Technological obsolescence
- Economic downturn
What Are SZLSF's Competitive Advantages?
- Proprietary Sentinel Principle platform technology
- Aristotle multi-cancer panel test offering a comprehensive screening solution
- Vertically integrated business model providing control over the entire value chain
What Does SZLSF Do?
Founded in 1998 and headquartered in Richmond Hill, Canada, StageZero Life Sciences Ltd. is a healthcare company focused on developing and commercializing molecular diagnostic tests. The company operates as a vertically integrated entity, handling the entire process from biomarker discovery to test commercialization. StageZero's primary focus is on early disease detection and personalized health management, with a strong emphasis on cancer-related indications. Their proprietary platform technology, Sentinel Principle, is designed to identify novel biomarkers from whole blood, enabling the development of highly sensitive and specific diagnostic tests. The company's flagship product is Aristotle, a multi-cancer panel test that simultaneously screens for multiple cancers from a single blood sample. In addition to Aristotle, StageZero offers ColonSentry, a blood test for assessing colorectal cancer risk, COVID-19 PCR testing, Prostate Health Index for prostate cancer screening, and BreastSentry for assessing breast cancer risk. StageZero Life Sciences Ltd. serves both the United States and Canadian markets.
What Products and Services Does SZLSF Offer?
- Develops molecular diagnostic tests for early disease detection.
- Commercializes diagnostic tests for personalized health management.
- Focuses primarily on cancer-related indications.
- Utilizes its proprietary Sentinel Principle platform to identify biomarkers.
- Offers the Aristotle multi-cancer panel test.
- Provides ColonSentry, a blood test for colorectal cancer risk assessment.
- Offers COVID-19 PCR testing and blood test analysis.
- Provides Prostate Health Index and BreastSentry screening tests.
How Does SZLSF Make Money?
- Develops and commercializes proprietary molecular diagnostic tests.
- Generates revenue through sales of diagnostic tests to healthcare providers and patients.
- Operates a vertically integrated business model, controlling the entire process from biomarker discovery to test commercialization.
What Industry Does SZLSF Operate In?
StageZero Life Sciences Ltd. operates within the medical diagnostics and research industry, a sector experiencing growth driven by advancements in molecular biology and personalized medicine. The increasing prevalence of cancer and the growing emphasis on early detection are fueling demand for innovative diagnostic solutions. The competitive landscape includes established players like Exact Sciences (EXAS) and smaller, specialized companies focused on specific cancer types. StageZero's multi-cancer screening approach differentiates it within the market, but it faces challenges in gaining market share and securing reimbursement in a competitive environment.
Who Are SZLSF's Key Customers?
- Healthcare providers (hospitals, clinics, physician groups)
- Patients seeking early disease detection and personalized health management
- Laboratories and research institutions
Company Profile
StageZero Life Sciences Ltd. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Richmond Hill, CA. The company is led by CEO James R. Howard-Tripp. SZLSF has traded publicly since 2009.
ROE 482%Key Financial Metrics
Return on equity for StageZero Life Sciences Ltd. stands at 481.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 2/9Financial Health
StageZero Life Sciences Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
FY2026 estForward Outlook
Wall Street analysts project StageZero Life Sciences Ltd. revenue of about $4.3M for fiscal 2026, with EPS near $-0.17.
SZLSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary Sentinel Principle platform
- Aristotle multi-cancer panel test
- Vertically integrated business model
- Focus on early disease detection
Bear Case
- Limited financial resources
- Small market capitalization
- Dependence on Aristotle test
- Low gross margin
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SZLSF Latest News
No recent news available for SZLSF.
SZLSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SZLSF.
Price Targets
Wall Street price target analysis for SZLSF.
SZLSF MoonshotScore
What does this score mean?
The MoonshotScore rates SZLSF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: James R. Howard-Tripp
CEO
James R. Howard-Tripp serves as the CEO of StageZero Life Sciences Ltd. His background includes extensive experience in the healthcare and biotechnology industries. He has held leadership positions in various companies, focusing on strategic development, commercialization, and financial management. His expertise spans across diagnostics, pharmaceuticals, and medical devices. He is responsible for managing 40 employees.
Track Record: Under James R. Howard-Tripp's leadership, StageZero Life Sciences has focused on the development and commercialization of its Aristotle multi-cancer panel test. Key milestones include securing partnerships with healthcare providers and expanding the test's availability. The company has also navigated the challenges of operating in the competitive diagnostics market and securing funding for its operations.
SZLSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that StageZero Life Sciences Ltd. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited information available to investors and are often subject to greater price volatility and risk compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier is typically reserved for companies that are distressed, defunct, or unwilling to meet the requirements of higher tiers.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume
- Greater price volatility compared to exchange-listed stocks
- Potential for limited or delayed financial disclosures
- Higher risk of fraud or manipulation
- Lack of regulatory oversight compared to major exchanges
- Verify the company's financial statements and disclosures.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or investigations involving the company.
- Review the company's capitalization structure and potential dilution.
- Development and commercialization of proprietary diagnostic tests
- Focus on early disease detection and personalized health management
- Presence in the healthcare sector
- Management team with experience in the healthcare industry
SZLSF Healthcare Stock FAQ
What does StageZero Life Sciences Ltd. do?
StageZero Life Sciences Ltd. is a vertically integrated healthcare company that develops and commercializes molecular diagnostic tests for the early detection of diseases, with a primary focus on cancer. Their main product is the Aristotle multi-cancer panel test, which screens for multiple cancers from a single blood sample using their proprietary Sentinel Principle platform. They also offer other tests like ColonSentry for colorectal cancer risk assessment.
What do analysts say about SZLSF stock?
As of 2026-03-15, there is no readily available analyst coverage for SZLSF due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the risks associated with investing in micro-cap stocks. Key valuation metrics are difficult to assess without analyst estimates, and growth considerations depend on the successful commercialization of Aristotle.
What are the main risks for SZLSF?
The main risks for StageZero Life Sciences Ltd. include competition from larger, more established diagnostic companies, regulatory hurdles in obtaining approvals for new tests, and challenges in securing reimbursement coverage from payers. The company's limited financial resources and dependence on the Aristotle test also pose significant risks. Furthermore, as an OTC-listed stock, SZLSF is subject to greater price volatility and liquidity risk.
What are the key factors to evaluate for SZLSF?
Evaluate SZLSF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does SZLSF data refresh on this page?
SZLSF's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SZLSF's recent stock price performance?
StageZero Life Sciences Ltd. (SZLSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Sentinel Principle platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SZLSF overvalued or undervalued right now?
StageZero Life Sciences Ltd. (SZLSF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SZLSF before investing?
Before investing in StageZero Life Sciences Ltd. (SZLSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for in-depth analysis.
- OTC listing introduces higher risk and uncertainty.